N. Elgeioushi

发表

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

P. LoRusso, H. Burris, J. Infante, 2019, Journal of Immunotherapy for Cancer.

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

N. Rizvi, J. Infante, A. Naing, 2020, Clinical Cancer Research.

Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).

J. Desai, S. Clarke, Dong-Wan Kim, 2021 .

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

R. Simms, S. Peng, T. Geppert, 2014, Arthritis Research & Therapy.

Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies

Diansong Zhou, M. Gibbs, S. Ren, 2022, Cancer Chemotherapy and Pharmacology.

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

J. Desai, Dong-Wan Kim, J. Bendell, 2023, Cancer Immunology, Immunotherapy.

Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab

B. Cheson, T. Kipps, A. Cuneo, 2013, Journal of Immunotherapy for Cancer.

Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia

J. Zaucha, M. André, D. Gladstone, 2014 .

Phase 2 Open-Label study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL

J. Zaucha, M. André, D. Gladstone, 2014 .

NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies

M. Konopleva, G. Fabbri, B. Davies, 2021, Blood.

Abstract CT183: First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors

A. El-Khoueiry, T. Marron, B. Carneiro, 2022, Cancer Research.

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

B. Cheson, T. Kipps, M. Federico, 2013 .